Driving Growth through New Product Planning and Strategic Alliances

If you are interested in related research, you can click on the links here for SM-117 and OP-98.

Sales and Marketing > New Product Development and Launch

Download Free Excerpt

View TOC and List of Exhibits

Study Snapshot

Key Findings

• More effective product alignment with corporate strategies.
• Improved selection of strategic alliances.
• Accelerated corporate growth.
• Enhanced product lifecycle management.
• Increased Return on Investment (ROI) for R&D and sales and marketing.

• An Executive Summary outlining five Key Project Findings.
• Lessons Learned and Top Challenges Matrices identify benchmark partners' top lessons learned and top challenges in managing new product planning and strategic alliances.
• Detailed Best Practices divided into three sections:

Human Resources - Techniques for hiring, training and developing top new product planning and strategic planning personnel.

Portfolio Prioritization and Optimization - Best practices for selecting and commercializing blockbuster products through excellent new product planning and strategic alliance systems.

Back to Top

Key Findings

The study findings compiled in this report identify three key operational areas that form the foundation of superior new product planning and strategic alliance departments.   Report findings are organized to help companies meet all of the following goals:

1. Align new product planning and strategic alliance goals with company strategy to drive growth.
2. Recruit and select new product planning and strategic alliance personnel with balanced science and business backgrounds to reduce training needs and ensure quality performance.
3. Position new product planning as a central hub for coordinating and managing multi-functional activities to increase internal support and optimize product and portfolio management.
4. Balance opportunism with existing therapeutic expertise to best target new product and new alliance selections.
5. Integrate new product planning and strategic alliance structures and processes to optimize corporate growth through new opportunities.
   

Clinical Trial Excellence Library Service  Excellent clinical trials can significantly reduce costs by preventing delayed product launch due to trial length... (ID OPS-85) Companies Profiled: 3M Pharmaceuticals, Sanofi-aventis, AAI Corporation, AAI Development, more ... Price: $23100.00   Free Excerpt Available

R&D Quality Assurance Excellence Library  A must-have for all pharmaceutical, biotech and medical device manufacturing executives, this Best Practices' R&D Quality Assurance bundle tells you everything you need to know about quality... (ID OPS-95) Companies Profiled: aaiPharma, Sanofi-aventis, Abbott, Abbott Laboratories, more ... Price: $21100.00   Free Excerpt Available

Market Research Excellence: Research and the Unfair Competitive Advantage  Best Practices’ Market Research series highlights best practices in market research... (ID SMS-169) Companies Profiled: 3M Pharmaceuticals, Sanofi-aventis, aaiPharma, Abbott Laboratories, more ... Price: $20735.00   Free Excerpt Available

Pharma Thought Leadership: Be a Thought Leader, Manage Influential Organizations, Launch a Winner  Best Practices’ Pharma Thought Leadership series examines thought leadership in the context of patient advocacy while creating effective relationships and global product launches... (ID SMS-156) Companies Profiled: Abbott Laboratories, Sanofi-aventis, AstraZeneca, Bristol-Myers Squibb, more ... Price: $18400.00

Pharmaceutical New Product Planning: Structure and Activities to Drive Growth and Profitability  Pharmaceutical and biotech companies are increasingly under pressure to deliver effective new products in shorter time frames while minimizing development costs... (ID PSM-229) Companies Profiled: Abbott Laboratories, Sanofi-aventis, Actelion, Alcon, more ... Price: $9000.00   Free Excerpt Available

Success Factors and Failure Points in Oncology Product Launches  The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the oncology therapeutic area... (ID PSM-267) Companies Profiled: GlaxoSmithKline, Bristol-Myers Squibb, Roche, Lilly, more ... Price: $8500.00   Free Excerpt Available

Success Factors and Failure Points in Metabolic Product Launches  The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the metabolic therapeutic area... (ID PSM-266) Companies Profiled: GlaxoSmithKline, Bristol-Myers Squibb, Roche, Lilly, more ... Price: $8500.00   Free Excerpt Available

Success Factors and Failure Points in Cardiovascular Product Launches  The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the cardiovascular therapeutic area... (ID PSM-264) Companies Profiled: GlaxoSmithKline, Bristol-Myers Squibb, Roche, Lilly, more ... Price: $8500.00   Free Excerpt Available

Success Factors and Failure Points in Biopharmaceutical Product Launches: An Updated Road Map for Strong Market Entry  The last several years have been marked by dozens of pharmaceutical product launches; some products took off at launch while many others fell flat... (ID PSM-261) Companies Profiled: Abbott Laboratories, Amgen, Actelion, AstraZeneca, more ... Price: $8500.00   Free Excerpt Available

New Product Launch Spend: What It Takes To Win In The U.S. Market  In today’s pharmaceutical industry–where the recent product launch landscape is marked by as many failures as successes—it is critical for launch teams to understand the right level of resources required to give each new product its best chance for gaining a market foothold... (ID PSM-262) Companies Profiled: Abbott, ProStrakan, Sanofi-aventis, Regeneron, more ... Price: $8000.00   Free Excerpt Available

Educating KOLs, Physicians, Patients and Payers to Support Successful Product Launches  The bio-pharmaceutical marketplace continues to evolve as new medicines and technologies create valuable market opportunities... (ID PSM-248) Companies Profiled: GlaxoSmithKline, ARIAD, Pfizer, Integrated Communications Corp., more ... Price: $8000.00   Free Excerpt Available

Educating the Marketplace to Support Successful Diabetes Product Launches  The bio-pharmaceutical marketplace – including the diabetes therapeutic area – continues to evolve as new medicines and technologies create valuable market opportunities... (ID PSM-246) Companies Profiled: GlaxoSmithKline, ARIAD, Pfizer, Integrated Communications Corp., more ... Price: $8000.00   Free Excerpt Available

Shaping the Marketplace to Support Successful Oncology Product Launches: Tactics for Educating KOLs, Physicians, Patients and Payers  The bio-pharmaceutical marketplace – and the oncology therapeutic area in particular – continues to evolve as new medicines and technologies create valuable market opportunities... (ID PSM-243) Companies Profiled: GlaxoSmithKline, ARIAD, Pfizer, Integrated Communications Corp., more ... Price: $8000.00   Free Excerpt Available

Launching Pharmaceutical Megabrands: Best Practices in Marketing Blockbusters  The findings in this Best Practices Benchmarking® Report will enable pharmaceutical executives to understand the winning strategies, practices, team structures and investment patterns that distinguish successful new product development and marketing planning... (ID SM-124) Companies Profiled: Abbott Laboratories, Sanofi-aventis, Bristol-Myers Squibb, Amgen, more ... Price: $7962.00   Free Excerpt Available

Pharmaceutical New Product Commercialization: Preparing for Market Success  Long and costly product development cycles make it essential for pharmaceutical companies to maximize limited staff and resources to the development of compounds with the greatest potential market value... (ID SM-176) Companies Profiled: Abbott, Allergan, Alexion Pharmaceuticals, Altus Biologics, more ... Price: $7795.00   Free Excerpt Available

Best Practices in Working with Patient Advocacy Groups: Building Effective Relationships  Patient and professional advocacy groups play a crucial role in educating the marketplace on new medicines and treatments... (ID SM-185) Companies Profiled: Abaxis, Abbott Laboratories, Allos Therapeutics, Amgen, more ... Price: $7500.00   Free Excerpt Available

Best Practices for Internal Communications Regarding Brands & Disease State  When a promising new pharmaceutical product fails to meet expectations, poor brand communications may be a contributing cause... (ID POP-229) Companies Profiled: Abbott Laboratories, Sanofi-aventis, Actelion, Boehringer Ingelheim, more ... Price: $7400.00   Free Excerpt Available

Raising Disease State Awareness: Best Practices in Internal Brand Messaging for New Products  Educating the marketplace about disease state is crucial to the success of a new pharmaceutical product— especially if the product treats a medical condition that is previously unknown, socially sensitive or stigmatized or if the product is first in its class... (ID OP-106) Companies Profiled: Abbott, Novartis, Actelion, Novo Nordisk, more ... Price: $7200.00   Free Excerpt Available

Driving Growth Through Planning, Structure and Activities: Best Practices in Pharmaceutical New Product Planning  New products are the lifeblood of any biopharma company and organizations are increasingly under pressure to deliver effective products in shorter time frames... (ID SM-182) Companies Profiled: Abbott Laboratories, Sanofi-aventis, Actelion, Alcon, more ... Price: $7000.00   Free Excerpt Available

Best Practices in Global Pharmaceutical Launches  Discover how the world's leading pharmaceutical companies develop global launch strategies, manage launch teams, cultivate thought leader support, integrate marketing activities, and conduct a host of other critical launch activities... (ID SM-120) Companies Profiled: Merck, Sanofi-aventis, Eli Lilly, GlaxoSmithKline, more ... Price: $7000.00   Free Excerpt Available